The US Food and Drug Administration’s controversial recent approval of Alzheimer’s drug Aduhelm has been subject to vociferous criticism from many in the scientific community. Amidst concerns surrounding the drug’s efficacy and price, several expert advisors to the FDA have resigned in protest and…
